1,4-Dihydroxy-5,8-bis-propylamino-anthraquinone | 100495-30-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: 1,4-Dihydroxy-5,8-bis-propylamino-anthraquinone
• 英文别名: 1,4-Dihydroxy-5,8-bis(propylamino)anthracene-9,10-dione
• CAS: 100495-30-5
• 化学式: C₂₀H₂₂N₂O₄
• 分子量: 354.406
• InChiKey: YPRZHHRWSYNXTB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  98.7
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  5,8-Dihydroxy-1,4-bis-propylamino-2,3-dihydro-anthraquinone 在 苯并呋咱 作用下， 以 various solvent(s) 为溶剂， 反应 16.0h， 以92%的产率得到1,4-Dihydroxy-5,8-bis-propylamino-anthraquinone
  参考文献：
  名称：

  Dehydrogenations Using Benzofuroxan as Oxidant

  摘要：

  2-Arylsubstituted benzimidazoles, quinoxalines, in 3,5-position substituted 2,6-dimethylpyridines, and 1,4-bis(alkylamino)-9,10-anthracenediones are easily prepared under mild conditions by means of benzofuroxan as oxidant. Thus, the preparation of 2-arylbenzimidazoles succeeds in acetonitrile at 50-degrees-C in yields of 65 to 78 %.

  DOI：

  10.1080/00397919208021304

文献信息

• Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof
  申请人：The University of Chicago

  公开号：US11246877B2

  公开（公告）日：2022-02-15

  Prodrugs containing lipid moieties attached to drug derivatives, such as anti-cancer drug derivatives, via linkers comprising disulfide groups are described. Also described are nanoparticles coated with a lipid layer containing the prodrugs, formulations comprising the nanoparticles, and the use of the nanoparticles in methods of treating diseases, such as cancer, alone or in combination with additional drug compounds, targeting agents, and/or immunotherapy agents, such as immunosuppression inhibitors that target the CTLA-4, PD-1/PD-L1, IDO, LAG-3, CCR-7 or other pathways, or multiple immunosuppression inhibitors targeting a combination of such pathways. Optionally, the nanoparticles can comprise a photosensitizer or a derivative thereof and can be used in methods involving photodynamic therapy. Synergistic therapeutic effects result from combinations of multiple modalities provided by the disclosed nanoparticles and/or nanoparticle formulations.

  本文描述了含有脂质分子的原药，这些脂质分子通过包含二硫基团的连接体连接到药物衍生物（如抗癌药物衍生物）上。还描述了涂有包含原药的脂质层的纳米颗粒、包含纳米颗粒的制剂，以及纳米颗粒在治疗疾病（如癌症）的方法中的用途，单独使用或与其他药物化合物、靶向制剂和/或免疫疗法制剂（如靶向 CTLA-4、PD-1/PD-L1、IDO、LAG-3、CCR-7 或其他途径的免疫抑制抑制剂，或靶向此类途径组合的多种免疫抑制抑制剂）组合使用。可选地，纳米颗粒可包含光敏剂或其衍生物，并可用于涉及光动力疗法的方法中。所公开的纳米颗粒和/或纳米颗粒制剂提供的多种方式的组合可产生协同治疗效果。
• NEW COMPOUNDS AND USES THEREOF
  申请人：Biostatus Limited

  公开号：US20150307441A1

  公开（公告）日：2015-10-29

  An anthraquinone compound of formula I (such as the compounds of formulae II to X) and processes for making the same are provided. Pharmaceutical compositions for use in the treatment of cancer, optionally in combination with an agent capable of reducing the level of oxygenation of a tumour, are also provided. Additionally, an option for combination with chemotherapeutic and radiotherapeutic modalities to enhance overall tumour cell kill is provided. Methods for the detection of cellular hypoxia, both in vivo and in vitro, are additionally provided.
• NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF
  申请人：The University of Chicago

  公开号：US20190269706A1

  公开（公告）日：2019-09-05

  Prodrugs containing lipid moieties attached to drug derivatives, such as anti-cancer drug derivatives, via linkers comprising disulfide groups are described. Also described are nanoparticles coated with a lipid layer containing the prodrugs, formulations comprising the nanoparticles, and the use of the nanoparticles in methods of treating diseases, such as cancer, alone or in combination with additional drug compounds, targeting agents, and/or immunotherapy agents, such as immunosuppression inhibitors that target the CTLA-4, PD-1/PD-L1, IDO, LAG-3, CCR-7 or other pathways, or multiple immunosuppression inhibitors targeting a combination of such pathways. Optionally, the nanoparticles can comprise a photosensitizer or a derivative thereof and can be used in methods involving photodynamic therapy. Synergistic therapeutic effects result from combinations of multiple modalities provided by the disclosed nanoparticles and/or nanoparticle formulations.